Sexual & Hormonal Health
Peptides for Menopause & Perimenopause: Evidence-Ranked (2026)
A clinical, evidence-first ranking of the peptides marketed for the menopause transition — separating the one FDA-approved molecule from the population-borrowed, preclinical, and mechanistically backwards claims.
MenopausePerimenopauseLow libidoSkin & collagenHot flashes
The quick verdict
No peptide is FDA-approved for menopause and there are essentially no dedicated menopause peptide RCTs — here is the honest, evidence-ranked picture of PT-141, GHK-Cu, tesamorelin, CJC-1295 and kisspeptin-10.
- Best overall
- PT-141 (Bremelanotide) — The only peptide here with Grade-A, FDA-approved efficacy for low desire — but the approval is premenopausal-only, so postmenopausal use is off-label and unproven.
- Best value
- GHK-Cu (topical) — An inexpensive over-the-counter cosmetic with the most defensible human skin signal for the collagen loss of menopause — topical, not injectable.
- Best for Central/visceral fat and lean-mass loss
- Tesamorelin — The only GH-axis peptide with real human RCT evidence for visceral-fat reduction — though from HIV/diabetes cohorts, not dedicated menopause trials.
How we evaluated
We ranked each peptide strictly by the strength and applicability of its human evidence to the menopause transition, grading down every candidate whose data is borrowed from an adjacent population (premenopausal HSDD, photoaged skin, HIV visceral fat) rather than a dedicated menopause trial. We separate human RCT evidence from mechanistic human data, preclinical animal work, and anecdote, and we flag where a marketing claim runs backwards against the underlying biology. This is informational editorial content with a functional, root-cause lens — not medical advice and not a sourcing guide.
- Human evidence quality. Dedicated menopause RCTs weighted highest; borrowed-population RCTs, mechanistic human trials, preclinical and anecdote ranked below and graded down.
- Applicability to the menopause transition. Whether the studied population and symptom actually map to peri-/postmenopause, or whether the evidence is extrapolated across life stage or indication.
- Mechanistic coherence. Whether the peptide's biology plausibly helps the menopausal symptom — or, as with kisspeptin and hot flashes, pushes the wrong direction.
- Safety and regulatory status. FDA approval, contraindications relevant to midlife women, compounding status, and WADA anti-doping classification.
Rating scale: 1–5 stars, weighted toward applicable human evidence; preclinical-only and mechanistically-backwards candidates are rated honestly low regardless of marketing popularity.
Last verified .
At a glance
| # | Name | Evidence | Rating | Best for | Pricing |
|---|---|---|---|---|---|
| 1 | PT-141 (Bremelanotide / Vyleesi) | A | 4.0 | Premenopausal or early-transition women with acquired, generalized low desire (on-label); off-label and unproven postmenopause | Prescription (FDA-approved); varies by pharmacy |
| 2 | GHK-Cu (topical copper tripeptide) | B | 3.5 | Menopausal skin thinning, fine lines and reduced density — as a topical adjunct, not a systemic fix | OTC cosmetic (topical); varies by product |
| 3 | Tesamorelin (GHRH analog) | B | 3.0 | Menopausal central/visceral fat and lean-mass loss — where the patient understands the evidence is borrowed | Prescription (FDA-approved for a different indication); varies by pharmacy |
| 4 | CJC-1295 without DAC (Mod GRF 1-29) | D | 1.5 | Understanding what NOT to conflate with tesamorelin — the human evidence people cite is for a different molecule | Not FDA-approved; sold as research chemical (not for human use) |
| 5 | Kisspeptin-10 | B | 1.5 | Understanding why not to use kisspeptin for menopausal hot flashes — the biology argues against it | Investigational; no approved product |
PT-141 (Bremelanotide / Vyleesi)
The only FDA-approved peptide for low desire — but the approval stops at the menopausal threshold
Bremelanotide is the only peptide in this field with genuine Grade-A evidence, resting on two identical 24-week, randomized, double-blind, placebo-controlled Phase 3 trials (RECONNECT) enrolling roughly 1,247 to 1,267 women, plus a 52-week open-label extension. Versus placebo it produced statistically significant increases in sexual desire (FSFI-Desire +0.35 integrated, P<0.001) and reductions in desire-related distress, earning FDA approval on June 21, 2019. The menopause-critical caveat is decisive: the trials enrolled premenopausal women, and postmenopausal women were explicitly excluded from the label with efficacy never established in them. So the Grade-A evidence applies to premenopausal and early-transition desire, while for the postmenopausal state most people mean by "menopause," PT-141 is off-label and unproven (Grade D). The benefit is also modest — roughly a half-point on desire, no significant increase in satisfying sexual events, and authors estimated about 40% of the relative improvement was placebo. It is a synthetic cyclic heptapeptide that activates central melanocortin receptors (predominantly MC4R), targeting the brain rather than the bloodstream, dosed on demand about 45 minutes before activity.
Strengths
- Only peptide here with two large Phase 3 RCTs and an FDA approval (2019)
- Centrally acting on desire circuitry (MC4R), mechanistically distinct from PDE5 inhibitors
- On-demand dosing; 52-week extension showed sustained benefit with no new safety signals
Weaknesses
- Approved for PREmenopausal HSDD only — postmenopausal efficacy/safety never established (Grade D there)
- Modest effect size with ~40% attributed to placebo; no rise in satisfying sexual events
- Nausea in ~40%; contraindicated in uncontrolled hypertension or known cardiovascular disease; focal hyperpigmentation with frequent use
- Best for
- Premenopausal or early-transition women with acquired, generalized low desire (on-label); off-label and unproven postmenopause
- Pricing
- Prescription (FDA-approved); varies by pharmacy
Source: Kingsberg et al., RECONNECT Phase 3 RCTs, Obstet Gynecol 2019
GHK-Cu (topical copper tripeptide)
The most defensible peptide for menopausal skin — topical, not systemic
GHK-Cu is the strongest peptide answer to the skin face of menopause, and it is over-the-counter and topical rather than injectable. Estrogen withdrawal, more than chronological aging, drives dermal matrix breakdown: studies report up to roughly 30% loss of dermal type I and III collagen in the first five postmenopausal years, then about 2% per year, with parallel skin-thickness decline. Topical copper-tripeptide-1 delivers copper to lysyl oxidase (the enzyme that cross-links collagen and elastin), signals fibroblasts to synthesize collagen, elastin and proteoglycans, and modulates matrix metalloproteinases toward balanced remodeling. The human signal is real but graded B, not A: multiple 12-week cosmetic studies (a 71-woman facial cream, a 41-woman eye cream, a 67-woman study in ages 50–59 showing keratinocyte proliferation on biopsy) reported increased skin density and reduced fine lines, and one biopsy study found collagen increases in 70% of GHK-Cu users versus 50% for vitamin C and 40% for retinoic acid. One randomized nano-lipid-carrier design (Badenhorst 2016) reduced wrinkle volume about 55.8% and depth about 32.8%. The base leans on open-label and conference work in peri-/postmenopausal-aged women, not dedicated menopause cohorts, and injectable GHK-Cu has no controlled human efficacy data.
Strengths
- Repeated human signal for increased skin density and reduced wrinkle depth in the right age range
- Coherent mechanism countering estrogen-deficient collagen loss (lysyl oxidase + matrikine signaling)
- Inexpensive, over-the-counter, well tolerated topically; a reasonable non-hormonal adjunct
Weaknesses
- Evidence is topical-only and largely open-label/small-sample — not dedicated menopause RCTs (Grade B)
- Injectable/systemic GHK-Cu for menopause has NO controlled human efficacy data
- Absolute contraindication in Wilson's disease/copper-handling disorders and copper allergy
- Best for
- Menopausal skin thinning, fine lines and reduced density — as a topical adjunct, not a systemic fix
- Pricing
- OTC cosmetic (topical); varies by product
Source: Pickart & Margolina, GHK peptide in skin regeneration, Biomed Res Int 2015
Tesamorelin (GHRH analog)
Real human RCT evidence for visceral fat — but from a borrowed population
Tesamorelin is the evidence-backed member of the GH-axis peptide family and the honest answer for the central-fat and lean-mass shift of midlife. Across menopause, GH and IGF-1 decline ("somatopause") overlap estrogen loss, shifting body composition toward visceral fat and sarcopenia; the WHI substudy found estrogen-plus-progestin partly preserved lean tissue, an effect thought partly GH/IGF-1-mediated. Tesamorelin is a GHRH analog that stimulates the body's own somatotrophs to release GH in pulses, raising IGF-1 and mobilizing visceral fat via lipolysis while preserving feedback, unlike injected recombinant GH. It is FDA-approved (2010) for excess visceral fat in HIV-associated lipodystrophy, and pivotal RCTs showed selective visceral-adipose-tissue reductions of roughly 15 to 18% over 26 weeks with subcutaneous fat largely spared. The population caveat is the whole story: postmenopausal women were included in some tesamorelin trials (e.g., a randomized placebo-controlled type-2-diabetes trial enrolling postmenopausal or surgically-sterilized women aged 50 and over), but no dedicated menopause or perimenopause visceral-fat RCT exists. So this is genuine Grade-B evidence for visceral fat, with the borrowed-population caveat made explicit — and with metabolic and theoretical cancer cautions that matter for midlife women.
Strengths
- Real human RCT evidence for ~15–18% visceral-fat reduction; FDA-approved (2010) for HIV lipodystrophy
- Pulsatile, feedback-preserving GH release rather than exogenous recombinant GH
- Postmenopausal women included in some trials, making the extrapolation less of a leap than for CJC-1295
Weaknesses
- No dedicated menopause/perimenopause RCT — all efficacy data is from HIV and diabetes cohorts
- Can cause insulin resistance, fluid retention and arthralgia; theoretical IGF-1-mediated tumor concern relevant to midlife breast-cancer risk
- Prohibited at all times in sport (WADA S2); contraindicated with active malignancy, uncontrolled diabetes, pregnancy/lactation
- Best for
- Menopausal central/visceral fat and lean-mass loss — where the patient understands the evidence is borrowed
- Pricing
- Prescription (FDA-approved for a different indication); varies by pharmacy
Source: Stanley & Grinspoon et al., GHRH on visceral fat, 2014
CJC-1295 without DAC (Mod GRF 1-29)
The molecule consumers actually buy for menopause — with no human RCT at all
CJC-1295 without DAC (Mod GRF 1-29) is the peptide most aggressively marketed for "menopause recovery" and body recomposition, usually stacked with ipamorelin — and it is the weakest evidence in this ranking. The exact short-acting no-DAC molecule that consumers buy has no published human RCT. Its GH-releasing pharmacology is documented only in animals and cells: roughly 4-fold GH area-under-curve versus native GRF in rats, and the original Hoffmann-La Roche substitution chemistry was about 11 to 13-fold more potent in vivo in pigs. The human RCTs people cite tested the DAC version or the native sequence, not the short-acting no-DAC product. That means the popular menopause weight-gain and muscle-loss claims are anecdotal and mechanistic (Grade D) — biologically plausible, but not demonstrated by any controlled menopause trial. It carries the same GH-axis safety concerns as tesamorelin (insulin resistance, fluid retention, arthralgia, theoretical IGF-1-mediated tumor and angiogenesis risk), and because it is sold on the unregulated "research chemical" market it adds immunogenicity and impurity hazards on top. It is also prohibited at all times in sport as a GHRH analog. The honest read: the actual human visceral-fat evidence belongs to tesamorelin, not to this molecule.
Strengths
- Documented GH-releasing pharmacology in animal and cell models (~4x GH AUC vs native GRF in rats)
- Mechanistically plausible for the same somatopause-driven body-composition shift as tesamorelin
- Short-acting no-DAC profile is theoretically more pulsatile/physiologic than the long-acting DAC version
Weaknesses
- The exact no-DAC molecule has NO published human RCT — menopause claims are anecdotal/mechanistic (Grade D)
- Sold as an unregulated "research chemical," adding immunogenicity and impurity risk to GH-axis metabolic hazards
- Not FDA-approved; not recommended for the 503A compounding bulks list; prohibited at all times in sport (WADA S2)
- Best for
- Understanding what NOT to conflate with tesamorelin — the human evidence people cite is for a different molecule
- Pricing
- Not FDA-approved; sold as research chemical (not for human use)
Source: Jetté et al., CJC-1295 identification (rat/in-vivo), Endocrinology 2005
Kisspeptin-10
The cautionary tale — mechanistically wrong-direction for hot flashes
Kisspeptin-10 is the clearest example in this field of marketing biology running backwards. It has genuine Grade-B mechanistic human data for sexual brain processing: in randomized, placebo-controlled crossover trials, intravenous kisspeptin modulated sexual brain responses in women with HSDD, a parallel men's trial augmented penile tumescence up to about 56% over placebo, and kisspeptin-10 raises LH dose-dependently in humans as proof of axis engagement. But these are proof-of-mechanism studies on neuroimaging and physiology surrogates, not real-world outcome trials, and they were run predominantly in reproductive-age adults rather than menopausal women. The decisive problem is the KNDy paradox. At menopause, estrogen withdrawal hyperactivates the kisspeptin/neurokinin-B/dynorphin (KNDy) neurons of the hypothalamic arcuate nucleus, and excess neurokinin-B signaling through NK3R is the proximate driver of hot flashes. The validated therapeutic direction is therefore to block that pathway — which is why the NK3R antagonist fezolinetant was FDA-approved in 2023 for vasomotor symptoms and the dual antagonist elinzanetant cut VMS frequency about 65% in Phase 3. A kisspeptin agonist amplifies KNDy output, the opposite of what hot-flash relief requires. There is no approved product, no validated outpatient regimen, and frequent dosing causes tachyphylaxis; it was reviewed at the October 2024 FDA PCAC and recommended against the 503A compounding bulks list.
Strengths
- Genuine Grade-B mechanistic human data for sexual brain processing and LH stimulation
- Well tolerated in short research infusions
- Illustrates real proof-of-mechanism for desire circuitry — in the correct (reproductive-age) direction
Weaknesses
- Mechanistically WRONG-direction for hot flashes — kisspeptin agonism amplifies the KNDy overactivity that CAUSES them
- Human evidence is mechanistic-only and in reproductive-age adults, not menopausal women
- No approved product, tachyphylaxis with frequent dosing, prohibited in sport, and recommended against the 503A bulks list (2024 PCAC)
- Best for
- Understanding why not to use kisspeptin for menopausal hot flashes — the biology argues against it
- Pricing
- Investigational; no approved product
Source: Comninos/Thurston et al., kisspeptin in women with HSDD RCT, JAMA Netw Open 2022
Frequently asked
Is any peptide FDA-approved for menopause?
No. No peptide is approved for "menopause." PT-141 (Vyleesi) is approved only for low sexual desire in premenopausal women with acquired, generalized HSDD, and tesamorelin is approved for HIV-associated visceral fat — neither is a menopause indication. The only recent FDA-approved non-hormonal drug for menopausal hot flashes, fezolinetant (Veozah), is a small-molecule NK3R antagonist, not a peptide. Much of what is sold online "for menopause" borrows evidence from adjacent populations, so the honest evidence picture is far narrower than the marketing suggests, and the foundational care remains hormone therapy where appropriate, resistance training, protein, and sleep.
Will PT-141 help low libido after menopause?
PT-141's proven, FDA-approved benefit is in premenopausal women; postmenopausal efficacy and safety were never established, and the label explicitly excludes them. Any postmenopausal use is off-label and unproven. Perimenopausal women who are still cycling sit closer to the studied population, but the pivotal RECONNECT trials did not specifically characterize a perimenopausal subgroup. Even in the approved population the effect size is modest — roughly a half-point on desire scales, with authors estimating about 40% of the relative improvement was placebo — and nausea affects around 40% of treated women. It is contraindicated in uncontrolled hypertension or known cardiovascular disease, a non-trivial caveat because cardiovascular risk rises across the transition.
Can kisspeptin help my hot flashes?
No — and mechanistically it could make them worse. Menopausal hot flashes are driven by overactive kisspeptin/neurokinin-B/dynorphin (KNDy) neurons in the hypothalamus: when estrogen withdraws, these neurons hypertrophy and over-secrete neurokinin B, triggering inappropriate heat dissipation. The validated therapeutic direction is to block that pathway, which is why NK3R antagonists like fezolinetant were approved for vasomotor symptoms. A kisspeptin agonist amplifies KNDy output — the opposite of what hot-flash relief requires. Kisspeptin's genuine human evidence is mechanistic-only, on sexual brain processing, and was gathered predominantly in reproductive-age adults rather than menopausal women.
Is topical GHK-Cu worth it for menopausal skin?
It is the most defensible peptide for the skin face of menopause — but topical, not injectable. Estrogen withdrawal drives up to roughly 30% loss of dermal collagen in the first five postmenopausal years, and topical copper-tripeptide has repeated human signal for increased skin density and reduced wrinkle depth. The evidence grades B, not A, because much of it comes from open-label and conference work plus small samples in peri- and postmenopausal-aged women, not dedicated menopause cohorts. Dermatology reviews note peptides and retinoids outperform topical estrogen for facial collagen. Injectable or systemic GHK-Cu for menopause has no controlled human efficacy data and is not a substitute for systemic care.
Do GH peptides reverse menopausal belly fat?
The honest answer is nuanced. Tesamorelin, a GHRH analog, reliably reduces visceral fat by roughly 15 to 18% in human RCTs — but those trials were in HIV-associated lipodystrophy and type-2-diabetes cohorts, not dedicated menopause populations, so the evidence is borrowed. The popular "CJC-1295 (no-DAC) plus ipamorelin" candidate that consumers actually buy has no published human RCT at all — only animal pharmacology and anecdote. Both carry real cautions: GH-axis stimulation can cause insulin resistance, fluid retention and arthralgia, plus a theoretical IGF-1-mediated tumor concern that is relevant given midlife breast-cancer and metabolic risk. The foundation remains resistance training and protein.
What does the strongest menopause care actually look like?
The largest, most durable treatment effects in the menopause transition come from addressing the root neuroendocrine event, not from peptides. That means menopausal hormone therapy where appropriate, resistance training and adequate protein to preserve muscle, sleep repair, and a workup of thyroid, metabolic and mood or relationship factors. A root-cause evaluation with a qualified clinician comes before any pharmacology. Peptides are, at most, narrow adjuncts to that foundation — and the placebo response in female sexual-function and vasomotor trials is large, so any honest reading keeps that front and center. Nothing in this ranking replaces systemic management or a clinician's individualized assessment.